The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

Published:2020-10 Issue: Volume:138 Page:68-76
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gebhardt Christoffer,Ascierto Paolo,Atkinson Victoria,Corrie Pippa,Dummer Reinhard,Schadendorf Dirk^ORCID

Funder

Novartis

Bristol Myers-Squibb

Roche-Genentech

Array

Roche

Amgen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference67 articles.

1. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine;Cheng;Mod Pathol,2018

2. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics;Lo;Science,2014

3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N Engl J Med,2014

5. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study;Molecular Cancer;2024-03-26

2. Rechallenge of immunotherapy in non-small cell lung cancer patients — navigating indications and evolving perspectives;Oncology in Clinical Practice;2024-01-24

3. BRAF/MEK inhibitor rechallenge in advanced melanoma patients;Cancer;2024-01-10

4. Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis;Cancers;2023-07-25

5. The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review;Cancers;2023-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3